Luis Pereira de Almeida
Overview
Explore the profile of Luis Pereira de Almeida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
3909
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferreira-Marques M, Carmo-Silva S, Pereira J, Botelho M, Nobrega C, Lopez-Otin C, et al.
Geroscience
. 2025 Feb;
PMID: 40011349
The hypothalamus has been recognized as a regulator of whole-body aging. Neuropeptide Y (NPY), highly abundant in the central nervous system and produced by the hypothalamus, enhances autophagy in this...
2.
Berger M, Garcia-Moreno H, Ferreira M, Hubener-Schmid J, Schaprian T, Wegner P, et al.
medRxiv
. 2025 Feb;
PMID: 39974031
Background: Spinocerebellar ataxia type 3 (SCA3) is an autosomal dominantly inherited adult-onset disease. We aimed to describe longitudinal changes in clinical and biological findings and to identify predictors for clinical...
3.
Vaz M, Soares Martins T, Leandro K, de Almeida L, da Cruz E Silva O, Nunes A, et al.
Molecules
. 2025 Jan;
30(2).
PMID: 39860128
Alzheimer's disease is a challenge in modern healthcare due to its complex etiology and increasing prevalence. Despite advances, further understanding of Alzheimer's disease pathophysiology is needed, particularly the role of...
4.
Elter T, Sturm D, Santana M, Schaprian T, Raposo M, Melo A, et al.
J Neurol
. 2024 Dec;
272(1):54.
PMID: 39666145
Introduction: Knowledge about the distribution and frequency of the respective haplotypes on the wildtype and mutant allele is highly relevant in the context of future gene therapy clinical studies in...
5.
Colaco M, Cruz M, de Almeida L, Borges O
Pharmaceutics
. 2024 Oct;
16(10).
PMID: 39458637
Background/objectives: Nasal vaccines are a promising strategy for enhancing mucosal immune responses and preventing diseases at mucosal sites by stimulating the secretion of secretory IgA, which is crucial for early...
6.
Rodrigues B, Leitao R, Santos M, Trofimov A, Silva M, Inacio A, et al.
Mol Psychiatry
. 2024 Sep;
30(3):1034-1046.
PMID: 39237722
Chronic stress exerts profound negative effects on cognitive and emotional behaviours and is a major risk factor for the development of neuropsychiatric disorders. However, the molecular links between chronic stress...
7.
Leandro K, Rufino-Ramos D, Breyne K, Di Ianni E, Lopes S, Nobre R, et al.
Adv Drug Deliv Rev
. 2024 Jun;
211:115346.
PMID: 38849005
Gene editing technologies have the potential to correct genetic disorders by modifying, inserting, or deleting specific DNA sequences or genes, paving the way for a new class of genetic therapies....
8.
de Sousa-Lourenco J, Silva A, de Almeida L, Nobre R
Trends Mol Med
. 2024 Jun;
30(9):804-808.
PMID: 38839514
Polyglutamine (polyQ) disorders are monogenic neurodegenerative disorders. Currently, no therapies are available for this complex group of disorders. Here, we aim to provide an overview of recent promising preclinical studies...
9.
Moreira R, Nobrega C, de Almeida L, Mendonca L
J Nanobiotechnology
. 2024 May;
22(1):260.
PMID: 38760847
Neurodegenerative diseases are characterized by extensive loss of function or death of brain cells, hampering the life quality of patients. Brain-targeted drug delivery is challenging, with a low success rate...
10.
Lopes M, Lopes S, Baganha R, Henriques C, Silva A, Lobo D, et al.
J Vis Exp
. 2024 Apr;
(206).
PMID: 38647283
Adeno-associated virus (AAV) has become an increasingly valuable vector for in vivo gene delivery and is currently undergoing human clinical trials. However, the commonly used methods to purify AAVs make...